Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nasus Pharma(NSRX) the EBIT is -6.041 M (--%), Miss estimate;the EPS is -0.54 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B--
-0.00B--
-0.00B--%
EPSMiss expectations
-0.54--
-0.23--
-0.3100--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf